Search Results - "Coleman, Robert E."

Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity by COLEMAN, Robert E

“…The skeleton is the most common organ to be affected by metastatic cancer and the site of disease that produces the greatest morbidity. Skeletal morbidity…”
Get full text

Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment by Tulotta, Claudia, Lefley, Diane V, Freeman, Katy, Gregory, Walter M, Hanby, Andrew M, Heath, Paul R, Nutter, Faith, Wilkinson, J Mark, Spicer-Hadlington, Amy R, Liu, Xinming, Bradbury, Steven M J, Hambley, Lisa, Cookson, Victoria, Allocca, Gloria, Kruithof de Julio, Marianna, Coleman, Robert E, Brown, Janet E, Holen, Ingunn, Ottewell, Penelope D

“…Breast cancer bone metastases are incurable, highlighting the need for new therapeutic targets. After colonizing bone, breast cancer cells remain dormant,…”
Get full text

Bisphosphonates as treatment of bone metastases by Holen, Ingunn, Coleman, Robert E

“…Accelerated bone loss is a common clinical feature of advanced breast cancer, and anti-resorptive bisphosphonates are the current standard therapy used to…”
Get more information

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial by Forbes, John F, Prof, Sestak, Ivana, PhD, Howell, Anthony, Prof, Bonanni, Bernardo, MD, Bundred, Nigel, Prof, Levy, Christelle, MD, von Minckwitz, Gunter, Prof, Eiermann, Wolfgang, MD, Neven, Patrick, Prof, Stierer, Michael, Prof, Holcombe, Chris, MD, Coleman, Robert E, Prof, Jones, Louise, Prof, Ellis, Ian, Prof, Cuzick, Jack, Prof

“…Summary Background Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with…”
Get full text

Bisphosphonates: Clinical Experience by Coleman, Robert E.

“…Learning Objectives After completing this course, the reader will be able to: Explain the importance of bone disease in the common solid tumors of adulthood…”
Get full text

Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230 by EASTELL, Richard, ADAMS, Judith E, COLEMAN, Robert E, HOWELL, Anthony, HANNON, Rosemary A, CUZICK, Jack, MACKEY, John R, BECKMANN, Matthias W, CLACK, Glen

“…The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial (median follow-up, 68 months) has shown that adjuvant anastrozole has superior efficacy and…”
Get full text

Endocrine aspects of bone metastases by Hofbauer, Lorenz C, Prof, Rachner, Tilman D, MD, Coleman, Robert E, Prof, Jakob, Franz, Prof

“…Summary Skeletal lesions are a frequent complication of breast and prostate cancer and a hallmark of multiple myeloma. Endocrine and paracrine factors modulate…”
Get full text

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG by Hadji, Peyman, Aapro, Matti S., Body, Jean-Jacques, Gnant, Michael, Brandi, Maria Luisa, Reginster, Jean Yves, Zillikens, M. Carola, Glüer, Claus-C., de Villiers, Tobie, Baber, Rod, Roodman, G. David, Cooper, Cyrus, Langdahl, Bente, Palacios, Santiago, Kanis, John, Al-Daghri, Nasser, Nogues, Xavier, Eriksen, Erik Fink, Kurth, Andreas, Rizzoli, Rene, Coleman, Robert E.

“…Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase…”
Get full text

Chemotherapy following radium-223 dichloride treatment in ALSYMPCA by Sartor, Oliver, Hoskin, Peter, Coleman, Robert E., Nilsson, Sten, Vogelzang, Nicholas J., Petrenciuc, Oana, Staudacher, Karin, Thuresson, Marcus, Parker, Christopher

“…BACKGROUND Radium‐223 prolongs overall survival in patients with castration‐resistant prostate cancer (CRPC) and symptomatic bone metastases, regardless of…”
Get full text

Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial by Walsh, Jennifer S, Marshall, Helen, Smith, Isabelle L, Greenfield, Diana M, Swain, Jayne, Best, Emma, Ashton, James, Brown, Julia M, Huddart, Robert, Coleman, Robert E, Snowden, John A, Ross, Richard J

“…Young male cancer survivors have lower testosterone levels, higher fat mass, and worse quality of life (QoL) than age-matched healthy controls. Low…”
Get full text

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study by Coleman, Robert E, Prof, Banks, Linda M, DCR, Girgis, Samia I, MD, Kilburn, Lucy S, MSc, Vrdoljak, Eduard, MD, Fox, John, MD, Cawthorn, Simon J, FRCS, Patel, Ashraf, FRCS, Snowdon, Claire F, MSc, Hall, Emma, PhD, Bliss, Judith M, Prof, Coombes, R Charles, Prof

“…Summary Background Tamoxifen preserves bone in postmenopausal women, but non-steroidal aromatase inhibitors accelerate bone loss and increase fracture risk. We…”
Get full text

Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid by COLEMAN, Robert E, MAJOR, Pierre, COOK, Richard, LIPTON, Allan, BROWN, Janet E, LEE, Ker-Ai, SMITH, Matthew, SAAD, Fred, MING ZHENG, YONG JIANG HEI, SEAMAN, John

“…Three large, randomized trials of patients with bone metastases recently demonstrated that zoledronic acid reduces the risk of skeletal-related events. These…”
Get full text

Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer by LESTER, James E, DODWELL, David, PUROHIT, Omprakash P, GUTCHER, Sandra A, ELLIS, Susan P, THORPE, Ruth, HORSMAN, Janet M, BROWN, Janet E, HANNON, Rosemary A, COLEMAN, Robert E

“…Purpose: The aromatase inhibitor anastrozole is a highly effective well-tolerated treatment for postmenopausal endocrine-responsive breast cancer. However, its…”
Get full text

Potential Anticancer Properties of Bisphosphonates by Neville-Webbe, Helen L, Gnant, Michael, Coleman, Robert E

“…Bisphosphonates inhibit osteoclast-mediated bone resorption, which is increased when cancer cells invade bone, and are used in the treatment of metastatic bone…”
Get full text

Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group by Reid, David M, Doughty, Julie, Eastell, Richard, Heys, Steven D, Howell, Anthony, McCloskey, Eugene V, Powles, Trevor, Selby, Peter, Coleman, Robert E

“…Summary In postmenopausal women, the use of aromatase inhibitors increases bone turnover and induces bone loss at sites rich in trabecular bone at an average…”
Get full text

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study by BLISS, Judith M, KILBURN, Lucy S, DE VELDE, Cornelis J. H. Van, LONNING, Per E, MORDEN, James, REISE, Justine, CISAR, Laura, MENSCHIK, Thomas, COOMBES, R. Charles, COLEMAN, Robert E, FORBES, John F, COATES, Alan S, JONAS, Stephen E, JASSEM, Jacek, DELOZIER, Thierry, ANDERSEN, Jørn, PARIDAENS, Robert

“…Intergroup Exemestane Study (IES), an investigator-led study in 4,724 postmenopausal patients with early-stage breast cancer has demonstrated clinically…”
Get full text

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study by Awada, Ahmad, Dr Prof, Garcia, Agustin A, MD, Chan, Stephen, MD, Jerusalem, Guy H M, Prof, Coleman, Robert E, Prof, Huizing, Manon T, Prof, Mehdi, Aminder, MD, O'Reilly, Sue M, MD, Hamm, John T, MD, Barrett-Lee, Peter J, Prof, Cocquyt, Veronique, Prof, Sideras, Kostandinos, MD, Young, David E, MD, Zhao, Carol, MS, Chia, Yen Lin, PhD, Hoch, Ute, PhD, Hannah, Alison L, MD, Perez, Edith A, Prof

“…Summary Background New therapeutic options are needed for patients with heavily pretreated breast cancer. Etirinotecan pegol is a long-acting topoisomerase-I…”
Get full text

Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group by Brown, Janet E., Handforth, Catherine, Compston, Juliet E., Cross, William, Parr, Nigel, Selby, Peter, Wood, Steven, Drudge-Coates, Lawrence, Walsh, Jennifer S., Mitchell, Caroline, Collinson, Fiona J., Coleman, Robert E., James, Nicholas, Francis, Roger, Reid, David M., McCloskey, Eugene

“…•Bone health should be prioritised when men with prostate cancer start long-term ADT.•Assessment by FRAX (±bone mineral density) identifies those at highest…”
Get full text

Metastasis and bone loss: Advancing treatment and prevention by Coleman, Robert E, Lipton, Allan, Roodman, G. David, Guise, Theresa A, Boyce, Brendon F, Brufsky, Adam M, Clézardin, Philippe, Croucher, Peter I, Gralow, Julie R, Hadji, Peyman, Holen, Ingunn, Mundy, Gregory R, Smith, Matthew R, Suva, Larry J

“…Abstract Tumor metastasis to the skeleton affects over 400,000 individuals in the United States annually, more than any other site of metastasis, including…”
Get full text

Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy by Allan Lipton, Guenther G. Steger, Jazmin Figueroa, Cristina Alvarado, Philippe Solal-Celigny, Jean Jacques Body, Richard de Boer, Rossana Berardi, Pere Gascon, Katia S. Tonkin, Robert E. Coleman, Alexander H.G. Paterson, Guozhi M. Gao, Amy C. Kinsey, Mark C. Peterson, Susie Jun

“…Purpose: Denosumab, a fully human monoclonal antibody to RANKL, suppresses bone resorption. This study evaluated the effects of denosumab in i.v…”
Get full text